BIIB - Biogen Inc Qarzning balans kapitallashuviga nisbati

Biogen Corp (BIIB) kompaniyasining korporativ logotipi

Biogen Inc. ESG standartlarini joriy qilmoqda, iqlim neytralligiga erishdi va miyaga bo'lgan toksik ta'sirni minimallashtirdi. Bu esa rivojlantirish ishlari saxovatli moliyalashtirish bilan qo'llab-quvvatlanadigan yetakchi neyrobiologlarni jalb qilmoqda. Umumiy qarzdorlikning kitob qiymatidagi kapitalizatsiya koeffitsiyenti kapital tuzilmasining dinamikasini aks ettiradi, bunda qiymat 0.47 darajasida barqarorlashgan. Biroq, terapiyaning yuqori narxi sug'urta kompaniyalari tomonidan noroziliklarga sabab bo'lmoqda, bu esa kompaniyani chegirmalar taqdim etishga majbur qilmoqda.

Biogen Idec (BIIB) - Balans qiymatiga qarzlar 04.07.2022dan 27.10.2026gacha

Biogen Inc (BIIB) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari Biogen Inc.|BIIB - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati Biogen Idec|BIIB - Qarz va naqd pullar hisobga olingan qiymat
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar Biogen|BIIB - Kompaniyaning xususiy kapitali|Bozor kapitallashuvining balans qiymatiga nisbati biogen.com|BIIB - Kompaniyaning jami aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Biogen Inc.|BIIB - Uzoq muddatli qarzdorlikning kapitalga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati Biogen Corp|BIIB - Kompaniyaning umumiy yig'indi qarzi|Balans kapitallashuviga qarzlar Biogen Idec
Kompaniyaning fundamental tahlili:Biogen Inc., BIIB
Biogen Corp brendining mahsuloti

Ushbu ko'rsatkich umumiy kredit majburiyatlarining sof aktivlar qiymatiga nisbatini aks ettirib, moliyaviy leverajni va kapital tuzilmasining haddan tashqari qizib ketish xatarlarini baholash imkonini beradi. Qarzning kitob kapitalizatsiyasiga nisbatini tahlil qilish Biogen Inc. (BIIB) kompaniyasining majburiy chegirmalar va qat'iy narx cheklovlari orqali innovatsion dori vositalaridan tushadigan daromadlarni cheklaydigan sug'urta kompaniyalari bosimiga nisbatan barqarorligini aniqlashga yordam beradi.

Biogen Inc. raqobatchilari

Qarzning balans qiymatiga nisbati NBIX (Neurocrine Biosciences)|regencellbioscience.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Axsome Therapeutics, Inc. (AXSM)|ACAD: Qarzning sof aktivlarga nisbati|Qarzning balans kapitallashuviga nisbati XENE|Viking Therapeutics Corp (VKTX) - Balans qiymatiga qarzlar|Balans kapitallashuviga qarzlar Supernus Pharmaceuticals|Qarzning balans kapitallashuviga nisbati catalystpharma.com|DNLI (Denali Therapeutics Inc.) - Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar HRMY (Harmony Biosciences Inc)|BHVN: Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar Amylyx Corp AMLX|Balans kapitallashuviga qarzlar TRVI|PRAX - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar AVXL|CBLL (CeriBell Inc) - Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Prothena Corporation (PRTA)|Qarzning balans qiymatiga nisbati Alector Therapeutics (ALEC)|Annexon, Inc. (ANNX) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati omeros.com (OMER)|Balans kapitallashuviga qarzlar NGNE|AC Immune S.A. - Sof aktivlarga qarzlar|Voyager Pharma (VYGR) - Qarzning balans kapitallashuviga nisbati|NMRA - Qarzning balans qiymatiga nisbati|SCLX (Scilex Holding Company) - Balans kapitallashuviga qarzlar|Qarzning balans qiymatiga nisbati tevogen.com|ACOG: Qarzning balans qiymatiga nisbati|Sof aktivlarga qarzlar Cognition Therapeutics Inc.|Balans kapitallashuviga qarzlar Inhibikase (IKT)|Qarzning balans kapitallashuviga nisbati Cassava Pharma (SAVA)|Balans kapitallashuviga qarzlar ASRT|Sof aktivlarga qarzlar Coya Therapeutics Inc COYA|Balans kapitallashuviga qarzlar VTGN (VistaGen Therapeutics Inc)|OVID - Sof aktivlarga qarzlar|Acumen Pharma (ABOS) - Balans kapitallashuviga qarzlar|CRVO (CervoMed Corporation) - Qarzning balans kapitallashuviga nisbati|Qarzning balans kapitallashuviga nisbati Alterity Therapeutics Ltd. (ATHE)|Qarzning balans qiymatiga nisbati Clene Nanomedicine|PepGen Inc. - Balans kapitallashuviga qarzlar|Balans qiymatiga qarzlar Jupiter Neurosciences, Inc. JUNS|Qarzning balans qiymatiga nisbati RLMD (Relmada)|Annovis Bio Corporation - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Grace Tx (GRCE)|AIFF: Qarzning sof aktivlarga nisbati|Qarzning balans kapitallashuviga nisbati KLTO|NeuroSense Therapeutics Ltd. (NRSN) - Balans qiymatiga qarzlar|Balans kapitallashuviga qarzlar Reviva Pharmaceuticals Holdings|Qarzning balans kapitallashuviga nisbati MetaVia, Inc.|NRXS (NeurAxis, Inc.) - Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar HSDT (heliusmedical.com)|PASG: Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar Neuphoria Therapeutics, Inc. NEUP|Balans kapitallashuviga qarzlar NERV|ATHA - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar ADXN|ALZN (Alzamend Neuro) - Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati Cyclerion Therapeutics Inc. (CYCN)|Qarzning balans qiymatiga nisbati Protagenic (PTIX)|Pasithea Therapeutics (KTTA) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati cortigent.com (CRGT)|Balans kapitallashuviga qarzlar ATXI|brainstorm-cell.com - Sof aktivlarga qarzlar|Cara Therapeutics (CARA) - Qarzning balans kapitallashuviga nisbati|CHRO - Qarzning balans qiymatiga nisbati|ELYM (eliemtx.com) - Balans kapitallashuviga qarzlar|Qarzning balans qiymatiga nisbati Intra-Cellular Therapies, Inc.|LBPH: Qarzning balans qiymatiga nisbati|Sof aktivlarga qarzlar marinuspharma.com|Balans kapitallashuviga qarzlar NKGen Biotech (NKGN)|Qarzning balans kapitallashuviga nisbati NeuroBo Pharmaceuticals Inc (NRBO)|Balans kapitallashuviga qarzlar SAGE|Sof aktivlarga qarzlar Synaptogenix, Inc SNPX|Balans kapitallashuviga qarzlar TRVN (Trevena, Inc.)|VIGL - Sof aktivlarga qarzlar|Anew Medical (WENA) - Balans kapitallashuviga qarzlar|CERE (Cerevel Therapeutics Inc) - Qarzning balans kapitallashuviga nisbati